title: Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome.
abstract: Cancer-related anorexia and cachexia syndrome (CACS) is a complex multifactorial condition, with loss of lean body mass, chronic inflammation, severe metabolic derangements, reduced food intake, reduced physical activity, and poor quality of life as key symptoms. Cachexia recognizes different phases or stages, moving from precachexia through overt cachexia to advanced or refractory cachexia. The purpose of this review is to describe currently effective approaches for the treatment of cachexia, moving forward to drugs and treatments already shown to be effective but needing further clinical trials to confirm their efficacy. We then introduce novel promising investigational drugs and approaches which, based on a strong rationale from the most recent data on the molecular targets/pathways driving the pathophysiology of cachexia, need to be tested either in currently ongoing or appropriate future clinical trials to confirm their clinical potential. Although different drugs and treatments have been tested, we can speculate that a single therapy may not be completely successful. Indeed, considering the complex clinical picture and the multifactorial pathogenesis of CACS, we believe that its clinical management requires a multidisciplinary and multitargeted approach. In our opinion, appropriate treatment for cachexia should target the following conditions: inflammatory status, oxidative stress, nutritional disorders, muscle catabolism, immunosuppression, quality of life, and above all, fatigue. A comprehensive list of the most interesting and effective multitargeted treatments is reported and discussed, with the aim of suggesting the most promising with regard to clinical outcome. A critical issue is that of testing therapies at the earliest stages of cachexia, possibly at the precachexia stage, with the aim of preventing or delaying the development of overt cachexia and thereby obtaining the best possible clinical outcome for patients.
authors: Department of Medical Oncology, University of Cagliari, Monserrato, Cagliari, Italy. mantovan@medicina.unica.it
authors: Giovanni
authors: G
authors: Mantovani
authors: Clelia
authors: C
authors: Madeddu
authors: Antonio
authors: A
authors: Macciò
keywords: cachexia staging; metabolic derangements; multimodal therapy; nutritional status; proinflammatory cytokines; quality of life
references: Oncologist. 2010;15(2):200-11
references: 20156909
references: Free Radic Res. 2003 Feb;37(2):213-23
references: 12653210
references: Front Neuroendocrinol. 2010 Jan;31(1):79-84
references: 19822168
references: Support Care Cancer. 2013 Jan;21(1):129-37
references: 22699302
references: Front Neurosci. 2010 Jan 08;3:59
references: 20582290
references: Expert Opin Pharmacother. 2009 Jun;10(8):1359-66
references: 19445562
references: J Support Oncol. 2007 Apr;5(4):157-62; discussion 164-6, 183
references: 17500503
references: J Clin Oncol. 2002 Jan 15;20(2):567-73
references: 11786587
references: Eur J Cancer Clin Oncol. 1989 Dec;25(12):1817-21
references: 2698804
references: Br J Cancer. 2012 May 8;106(10):1583-6
references: 22510747
references: Am J Clin Nutr. 2010 Apr;91(4):1143S-1147S
references: 20164318
references: Biochem J. 2012 Aug 15;446(1):23-36
references: 22621320
references: Am J Physiol Regul Integr Comp Physiol. 2011 Sep;301(3):R716-26
references: 21677277
references: Nutr Cancer. 2007;59(1):14-20
references: 17927497
references: Gynecol Oncol. 1998 Jun;69(3):248-52
references: 9648596
references: J Cachexia Sarcopenia Muscle. 2011 Dec;2(4):201-207
references: 22207908
references: BioDrugs. 2005;19(3):179-87
references: 15984902
references: J Intern Med. 2010 Jun;267(6):543-60
references: 20210843
references: J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):163-174
references: 21966642
references: Drugs. 2001;61(4):499-514
references: 11324680
references: Nutrition. 2008 Sep;24(9):806-14
references: 18725076
references: Lancet Oncol. 2011 May;12(5):489-95
references: 21296615
references: Br Med J (Clin Res Ed). 1984 Jan 7;288(6410):27
references: 6418303
references: Annu Rev Med. 2011;62:265-79
references: 20731602
references: Cancer Treat Rep. 1985 Jul-Aug;69(7-8):751-4
references: 2410117
references: J Pain Symptom Manage. 2004 Apr;27(4):360-9
references: 15050664
references: Cancer Res. 2004 Sep 15;64(18):6725-31
references: 15374990
references: Oncologist. 2010;15(2):119-21
references: 20133501
references: Nutr Clin Pract. 2006 Feb;21(1):68-81
references: 16439772
references: J Am Med Dir Assoc. 2011 Jan;12(1):62-7
references: 21194662
references: Expert Opin Biol Ther. 2011 Dec;11(12):1663-8
references: 21995322
references: Crit Rev Oncog. 1998;9(2):99-106
references: 9973244
references: Int J Cardiol. 2010 Oct 29;144(3):347-9
references: 20561693
references: Clin Nutr. 2008 Dec;27(6):793-9
references: 18718696
references: Cancer. 1974 Jun;33(6):1607-9
references: 4135151
references: J Clin Oncol. 2004 Jun 15;22(12):2469-76
references: 15197210
references: Physiol Rev. 2009 Apr;89(2):381-410
references: 19342610
references: Clin Nutr. 2012 Apr;31(2):176-82
references: 22047681
references: Eur J Cancer Clin Oncol. 1989 Dec;25(12):1823-9
references: 2483687
references: Cancer Res. 1971 Feb;31(2):98-107
references: 5545274
references: J Pain Symptom Manage. 2004 Jan;27(1):85-95
references: 14711473
references: Curr Opin Support Palliat Care. 2009 Dec;3(4):263-8
references: 19713854
references: Cell. 2010 Aug 20;142(4):531-43
references: 20723755
references: Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1030-4
references: 16702388
references: Eur J Immunol. 1993 Aug;23(8):1889-94
references: 8344351
references: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004310
references: 15846706
references: Histol Histopathol. 2007 Jul;22(7):805-14
references: 17455154
references: Br J Cancer. 1999 Feb;79(3-4):495-500
references: 10027319
references: Gynecol Oncol. 2012 Mar;124(3):417-25
references: 22198049
references: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD008664
references: 22513961
references: J Mol Med (Berl). 2010 Jan;88(1):85-92
references: 19802504
references: Cancer. 2004 May 1;100(9):1967-77
references: 15112279
references: J Clin Oncol. 2013 Apr 1;31(10):1271-6
references: 23439759
references: J Clin Oncol. 1996 Apr;14(4):1077-84
references: 8648360
references: Gut. 2005 Apr;54(4):540-5
references: 15753541
references: Head Neck. 2008 Jan;30(1):67-74
references: 17615567
references: Crit Rev Oncog. 2012;17(3):293-303
references: 22831160
references: Eur J Cancer. 2008 May;44(8):1124-32
references: 18375115